Cite this as: Wen CAO, Shunnan YAO, Anqi LI, Haoguang CHEN, Enfan ZHANG, Liqin CAO, Jinna ZHANG, Yifan HOU, Zhenfeng DAI, Jing CHEN, Xi HUANG, Li YANG, Zhen CAI. CUDC-101 as a dual-target inhibitor of EGFR and HDAC enhances the anti-myeloma effects of bortezomib by regulating G2/M cell cycle arrest[J]. Journal of Zhejiang University Science B, 2023, 24(5): 442-454.
http://doi.org/10.1631/jzus.B2200465


CUDC-101 as a dual-target inhibitor of EGFR and HDAC enhances the anti-myeloma effects of bortezomib by regulating G2/M cell cycle arrest

Key words: Multiple Myeloma; Bortezomib; CUDC-101; Cell cycle

Research Summary

This study mainly focused on the anti-myeloma ability and mechanism of CUDC-101 and summarized the key roles they played in the following aspects:

- **Strong potent anti-myeloma**
- **Induce G2/M cycle arrest**
- **Synergistic with bortezomib**



Created with Figdraw

JZUSTB

Innovation points

Highlights of this study

- **CUDC-101 has strong anti-myeloma ability in MM cell lines and primary MM cells**
- **CUDC-101 has limited damage caused to normal human cells**
- **CUDC-101 could induce G2/M cycle arrest in MM cells**
- **CUDC-101 and bortezomib have synergistic anti-myeloma effects**

JZUS-B